

# ForPatients

by Roche

[Renal Cell Cancer \(RCC\)](#) [Pancreatic Cancer](#) [Solid Tumors](#) [Malignant Melanoma](#) [Renal Cell Carcinoma](#) [Cancer Sarcoma](#) [Non Hodgkin Lymphoma \(NHL\)](#) [Lymphoma](#) [Colorectal Cancer \(CRC\)](#) [Non Small Cell Lung Carcinoma](#) [Ovarian Cancer](#) [Breast Cancer](#) [Thyroid Cancer](#) [Melanoma](#) [Head and Neck Neoplasms](#) [Head and Neck Cancer](#)

## **Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)**

**Trial Status**  
Active, not recruiting

**Trial Runs In**  
16 Countries

**Trial Identifier**  
NCT02568267  
2015-003385-84,GO40782  
RXDX-101-02

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT02568267 2015-003385-84,GO40782 RXDX-101-02**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---